|By PR Newswire||
|April 14, 2014 08:17 AM EDT||
LONDON, April 14, 2014 /PRNewswire/ --
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Achillion Pharmaceuticals Inc.'s stock recorded a trading volume of 1.95 million shares, as compared with its three months average volume of 1.90 million shares. The stock ended the day at $2.88, down 4.00%, after trading between $2.84 and $3.10. Achillion Pharmaceuticals Inc.'s shares have plummeted 5.57% in the previous three trading sessions, 10.56% in the last one month and 13.23% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages. Achillion Pharmaceuticals Inc.'s 200-day moving average of $4.41 is above its 50-day moving average of $3.36. Further, the stock has a Relative Strength Index (RSI) of 36.60. Sign up today to read free research on ACHN at:
On Friday, Medivation Inc. finished the session 5.56% lower at $55.08. A total of 1.63 million shares were traded, which is above its three months average volume of 1.53 million shares. The stock fluctuated between $55.00 and $59.24 during the session. Medivation Inc.'s stocks have plummeted 8.78% in the previous three trading sessions, 20.70% in the last one month and 13.69% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $71.68 and $63.35, respectively. Furthermore, the stock has an RSI of 28.91. Sign up today to read free research on MDVN at:
Shares in Mast Therapeutics Inc. fluctuated between $0.55 and $0.62 before ending Friday's session 11.36% lower at $0.55. Mast Therapeutics Inc.'s stock reported a trading volume of 3.51 million shares, as compared with its three months average volume of 4.04 million shares. Mast Therapeutics Inc.'s shares have declined 14.46% in the previous three trading sessions, 31.25% in the last one month, but the same has gained18.95% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $0.77 and $0.56, respectively. Additionally, the stock has an RSI of 25.95. Sign up today to read free research on MSTX at:
On Friday, Athersys Inc.'s stock plummeted 4.98%, to close the day at $2.86. The stock recorded trading volume of 0.79 million shares, as compared with its three months average volume of 1.26 million shares. The stock oscillated between $2.83 and $2.99 during the trading session. Athersys Inc.'s shares have declined 4.67% in the previous three trading sessions, 22.28% in the last one month, while the same has advanced 14.40% on YTD basis. The stock is trading above its 200-day moving average. Athersys Inc.'s 50-day moving average of $3.56 is above its 200-day moving average of $2.44. Furthermore, the company's shares have an RSI of 29.51. Sign up today to read free research on ATHX at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Aug. 29, 2016 08:15 AM EDT Reads: 733
Aug. 29, 2016 08:00 AM EDT Reads: 833
Aug. 29, 2016 08:00 AM EDT Reads: 922
Aug. 29, 2016 07:30 AM EDT Reads: 802
Aug. 29, 2016 03:00 AM EDT Reads: 2,416
Aug. 29, 2016 02:15 AM EDT Reads: 2,223
Aug. 29, 2016 02:15 AM EDT Reads: 1,830
Aug. 29, 2016 01:45 AM EDT Reads: 2,192
Aug. 29, 2016 01:15 AM EDT Reads: 3,021
Aug. 29, 2016 01:00 AM EDT Reads: 2,260
Aug. 29, 2016 12:00 AM EDT Reads: 1,909
Aug. 28, 2016 11:15 PM EDT Reads: 2,165
Aug. 28, 2016 10:30 PM EDT Reads: 4,071
Aug. 28, 2016 08:30 PM EDT Reads: 1,858
Aug. 28, 2016 08:15 PM EDT Reads: 1,965